Browse the evidence

The EndoCompass project identifies strategic research priorities in endocrine science to address critical hormone-related health challenges.

Practitioners should focus on the identified research priorities to improve hormone health.

Research priorities include genetic/epigenetic factors, brain-periphery communication, and environmental influences.

Understanding these factors can guide research and interventions in endocrine health.

Up to half of patients discontinue obesity medications within 1 to 2 years due to various reasons.

Practitioners should be aware of high discontinuation rates and address barriers to adherence.

If not detected and treated early, MASLD can progress to fibrosis and hepatocellular carcinoma.

Early detection and treatment of MASLD are crucial to prevent serious complications.

Further long-term, randomized, double-blind clinical trials are needed to confirm the efficacy and safety of tirzepatide.

Clinicians should be aware that more research is needed before fully endorsing tirzepatide as a treatment.

Future research should prioritize mechanistic human studies, real-world cardiovascular outcomes, and equity in drug access.

Practitioners and researchers should advocate for studies that address these areas to improve understanding and access to treatments.

In 2022, over 890 million adults were living with obesity, representing 43% of adults aged 18 years and over.

Health practitioners should recognize the significant prevalence of obesity in adult populations.

There is a biologically plausible link between GLP-1 RAs and pathways central to periodontal inflammation and host response.

Understanding this link may guide future research on periodontal treatments.

Tirzepatide reverses β-cell dedifferentiation in HFD-fed mice.

Tirzepatide may help restore β-cell function by reversing dedifferentiation in diabetic conditions.

The oleogel-in-oleogel system reduces in vitro digestibility by 17%–26% compared to control oleogels and up to 33% compared to single-component oleogels.

This system may help in reducing caloric intake from fats, aiding in obesity management.

The type of outer oleogel affects the digestibility of the oleogel-in-oleogel system.

Choosing the right outer oleogel could optimize the digestibility of fat substitutes.

Inhibiting the Group-specific component (GC) gene may provide a novel therapeutic target for treating metabolic diseases.

Practitioners may consider exploring GC inhibition as a treatment option for metabolic diseases.

GC ablation in mice fed a high fat diet protects against obesity and type 2 diabetes.

This suggests that targeting GC could be beneficial in preventing obesity in high-fat diet scenarios.

Inhibiting GC does not lead to reductions in food intake or lean mass.

This indicates that GC inhibition could be a safer alternative to current treatments that suppress appetite.

GLP-1 RA-induced gastroparesis can increase the risk of aspiration during ophthalmic surgery.

Surgeons should be aware of the aspiration risk in patients using GLP-1 RAs.

Preoperative screening and interdisciplinary coordination are important for patients using GLP-1 RAs undergoing ophthalmic surgery.

Healthcare teams should ensure thorough preoperative assessments for these patients.

Adjustment for covariates differing between trial type and associated with BW reduction nullified the association between T2D status and weight loss (p = 0.93).

This suggests that addressing demographic and comorbid factors may improve weight loss outcomes in T2D patients.

GLP-1R agonists can improve cardiac contractility in human hearts.

Practitioners may consider GLP-1R agonists as a potential treatment to enhance heart contractility.

GLP-1R agonists raise cAMP levels in cardiac cells.

Understanding the role of cAMP may help in developing therapies targeting cardiac function.

Epicardial adipose tissue may contribute to arrhythmogenesis through pro-inflammatory and pro-fibrotic effects.

Addressing epicardial adipose tissue may be important in managing arrhythmias in obese patients.

Current evidence does not support a single dominant mechanism for the efficacy of GLP-1 receptor agonists.

Practitioners should consider multiple factors influencing the effectiveness of GLP-1 receptor agonists.

The DRL model decreased the time-to-therapeutic-dose by 20% in simulations.

Using a DRL agent can expedite achieving therapeutic doses for patients.

No effects of protein supplementation were observed on muscle volume, muscle strength, or return to sport (RTS).

Protein supplementation may not be beneficial during early rehabilitation for muscle strain injuries.

Dietary protein intake did not affect daily myofibrillar protein synthesis rates during immobilization.

Practitioners should note that increasing dietary protein may not mitigate muscle loss during short-term disuse.